Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade B 7.87 1.55% 0.12
ADAP closed up 1.55 percent on Friday, September 25, 2020, on 1.24 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ADAP trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish 1.55%
NR7 Range Contraction 1.55%
Stochastic Reached Oversold Weakness 1.55%
Older End-of-Day Gignals for ADAP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 2 days ago
Down 2 % 2 days ago
1.5x Volume Pace 2 days ago
Down 1% 2 days ago
Up 2% 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Virotherapy Cancer Immunotherapy Non Small Cell Lung Cancer Ovarian Cancer Multiple Myeloma Melanoma Adoptive Cell Transfer Oncolytics Biotech Hematological Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Breast And Lung Cancer

Is ADAP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.4
52 Week Low 0.709
Average Volume 737,080
200-Day Moving Average 5.78
50-Day Moving Average 8.70
20-Day Moving Average 8.71
10-Day Moving Average 9.31
Average True Range 0.76
ADX 19.92
+DI 19.15
-DI 29.36
Chandelier Exit (Long, 3 ATRs ) 8.65
Chandelier Exit (Short, 3 ATRs ) 9.65
Upper Bollinger Band 10.75
Lower Bollinger Band 6.68
Percent B (%b) 0.29
BandWidth 46.65
MACD Line -0.02
MACD Signal Line 0.14
MACD Histogram -0.1553
Fundamentals Value
Market Cap 735.99 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -7.95
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.46
Resistance 3 (R3) 8.41 8.16 8.36
Resistance 2 (R2) 8.16 8.01 8.19 8.33
Resistance 1 (R1) 8.02 7.92 8.09 8.07 8.30
Pivot Point 7.77 7.77 7.81 7.79 7.77
Support 1 (S1) 7.62 7.62 7.70 7.67 7.44
Support 2 (S2) 7.37 7.52 7.40 7.41
Support 3 (S3) 7.23 7.37 7.38
Support 4 (S4) 7.28